HM Payson & Co. Sells 969 Shares of Sanofi (NASDAQ:SNY)

HM Payson & Co. lowered its stake in Sanofi (NASDAQ:SNY) by 14.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,595 shares of the company’s stock after selling 969 shares during the quarter. HM Payson & Co.’s holdings in Sanofi were worth $322,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Financial Advocates Investment Management lifted its stake in shares of Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after buying an additional 206 shares in the last quarter. Pinnacle Associates Ltd. lifted its position in shares of Sanofi by 7.1% in the third quarter. Pinnacle Associates Ltd. now owns 12,077 shares of the company’s stock valued at $696,000 after acquiring an additional 798 shares in the last quarter. First Trust Direct Indexing L.P. lifted its position in shares of Sanofi by 3.1% in the third quarter. First Trust Direct Indexing L.P. now owns 26,359 shares of the company’s stock valued at $1,519,000 after acquiring an additional 791 shares in the last quarter. Fortitude Family Office LLC boosted its stake in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Sanofi by 69.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 56,230 shares of the company’s stock worth $3,241,000 after purchasing an additional 23,138 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SNY shares. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $57.50.

Sanofi Stock Up 0.7 %

Shares of SNY opened at $53.27 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market capitalization of $135.19 billion, a price-to-earnings ratio of 27.18, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. Sanofi has a 1 year low of $45.00 and a 1 year high of $58.97. The business’s 50 day simple moving average is $55.92 and its 200-day simple moving average is $51.96.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 earnings per share. Sanofi’s revenue was up 12.3% on a year-over-year basis. As a group, equities analysts expect that Sanofi will post 4.27 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.